Market Overview

Prima BioMed Shares Rally Following New Buy Rating, $6 Target From Roth Capital

  • Prima BioMed Ltd (ADR) (NASDAQ: PBMD) shares jumped 13 percent in premarket trading on December 31.
  • Roth Capital’s Joseph Pantginis initiated coverage of the company with a Buy rating and a price target of $6.
  • Initial clinical efficacy of LAG-3 has been promising, putting the company in a leading position in the development of new checkpoint inhibition pathways, Pantginis stated.

Prima BioMed’s shares have been highly volatile over the last few years, until May 2015, analyst Joseph Pantginis said. The reasons cited were:

  1. Mixed results from CVac studies
  2. Management changes

Pantginis added, however, that the company seems to have been transformed under the leadership of CEO Marc Voight, especially with acquisition of Immutep SA. Prima BioMed purchased Immutep for $25 million, in a transaction completed in October 2014.

LAG-3 [Lymphocyte-Activation Gene 3] is a major factor involved in the regulation of T-cells in immune responses. Prima BioMed announced in February 2015 that the product was now available for partnering.

Pantginis believes that Prima’s current CMO/CSO, Professor Frederic Triebel, was the key driver for the Immutep acquisition and the promise of LAG-3.

“We believe Prima is establishing a leadership role in immunotherapy and look at LAG-3 as a key new checkpoint inhibitor target. We believe the approach has further been validated by having partnerships with two global pharmas,” the analyst added, while recommending building positions in Prima BioMed.

Latest Ratings for PBMD

Apr 2016Maxim GroupInitiates Coverage onBuy
Dec 2015Roth CapitalInitiates Coverage onBuy
Dec 2015FBR CapitalInitiates Coverage onOutperform

View More Analyst Ratings for PBMD
View the Latest Analyst Ratings


Related Articles (PBMD)

View Comments and Join the Discussion!

Posted-In: Joseph Pantginis Roth CapitalAnalyst Color Long Ideas Initiation Analyst Ratings Trading Ideas

Latest Ratings

CAMTStifelInitiates Coverage On19.0
ELMDNorthland Capital MarketsInitiates Coverage On15.0
DKNGUBSInitiates Coverage On52.0
DIODTruist SecuritiesInitiates Coverage On84.0
TGTArgus ResearchUpgrades205.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at